Qual é o preço para GenSight Biologics S.A. (SIGHT)

O preço para GenSight Biologics S.A. (SIGHT) é $0.12715583

Qual é a capitalização de mercado para GenSight Biologics S.A. (SIGHT)

A capitalização de mercado para GenSight Biologics S.A. (SIGHT) é $20.73M

GenSight Biologics S.A. (SIGHT) Ações em Circulação

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Ano	Ações em circulação	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Ações em circulação

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Ações em circulação	Diferença	País
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Empresa

Ações em circulação

Diferença

País